Earnings ·
Vyome Holdings, Inc. reported financial results for the second quarter ended June 30, 2026, showing cash and cash…
HINDVyome Holdings, Inc
Vyome Holdings, Inc. reported financial results for the second quarter ended June 30, 2026, showing cash and cash equivalents of approximately $7.9 million as of June 30, 2026, compared to $5.0 million at year-end 2025. Total operating expenses were approximately $874,000, resulting in a net loss attributable to common shareholders of approximately $720,000, or $0.10 per basic and diluted share. The company advanced its lead VT-1953 program by receiving FDA feedback on its proposed pivotal clinical study strategy for malignant fungating wounds and signed an agreement with Impetis Biosciences to in-license two selective JAK inhibitor assets. Vyome Holdings, Inc. is a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions.